Mitochondria are essential organelles present in the vast majority of eukaryotic cells.
Introduction
Mitochondria are characteristic double-membrane organelles, consisting of an outer mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM). The space between both membranes is known as the intermembrane space and that surrounded by the IMM is known as the mitochondrial matrix. The IMM forms numerous folds known as the mitochondrial cristae. Their central function is the production of most of cellular energy (in the form of ATP) through coupling ADP phosphorylation to the dissipation of a proton gradient generated by proton pumping from the mitochondrial matrix to the intermembrane space. This process is executed by the oxidative phosphorylation (OXPHOS) system, formed by the four complexes (I to IV) of the electron transport chain plus the ATP synthase or Complex V, which is located at the cristae [1] . Nevertheless, mitochondria are involved in other important cell physiological processes such as fatty acids β-oxidation, pyrimidine synthesis, iron sulfur clusters-key cofactors synthesis [2, 3] , apoptosis [4] , calcium homeostasis [5] , reactive oxygen species (ROS) production [6] or cAMP/protein kinase A (PKA) signalling [7] . The mitochondria house their own genome, the mtDNA. The mammalian mtDNA is a 16,569 bp double-strand DNA (dsDNA) molecule which is organized and maintained within the nucleoids located in the mitochondrial matrix [8] . In mammals, the mtDNA encodes for 13 proteins (all of which are subunits of the OXPHOS system), 2 ribosomal RNA (rRNA) and 22 transfer RNA (tRNA) [9] . In the past years, novel open reading frames have been described in the mtDNA, such as humanin [10] , the mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) [11] and the small humanin-like peptide (SHLPs) [12] . In humans, it has been calculated that the mitochondrial proteome is composed of 1100-1900 proteins [13, 14] . As a consequence, ∼ 99% of the mitochondrial proteins are encoded by the nuclear DNA (nDNA). These nDNA genes are transcribed in the nucleus, translated in the cytosol and subsequently the proteins are imported into the mitochondria. Defects in genes participating in the biogenesis of the OXPHOS system are often the cause of diseases. They could be due to mutations in either nDNA genes or mtDNA genes, affecting structural subunits of the OXPHOS complexes, assembly factors or mtDNA-maintaining and -decoding machineries including replication, transcription, mtRNAs processing and translation [15] . Although the human mitochondrial diseases are considered as rare diseases, their global prevalence, taken all together, is ∼1 case in 8,000 in adults and ∼1 case in 25 ,000 in children [15] . Clinically, they are a heterogeneous group of diseases, which may be revealed at any age and affecting any tissue or can be multisystemic, although they are principally linked to cells with a high energy demand. Unfortunately, the coenzyme Q 10 (CoQ 10 ) deficiency syndrome is the only group of mitochondrial diseases with an effective treatment ( [16] ). The identification of the specific genetic defect in a patient suspected to have a mitochondrial disease is complicated due to the heterogeneous phenotypes caused by mutations in a same gene [15] . In addition, at least the 20% of the mitochondrial proteome is uncharacterized, and the biochemical function of these proteins remains unknown ( [17] ). Thus, the identification of new mitochondrial genes and the molecular process that they are involved in is essential in order to completely understand the genetic basis of the mitochondrial diseases. From 2006, there have been several milestones to predict non-described genes involved in mitochondrial OXPHOS diseases such as the computer program Maestro [18] and MitoCarta [19] and its updates MitoCarta2.0 [13] and MitoCarta+ [17] . At the same time, a similar mitochondrial proteome database, MitoMiner v3.1, was developed [14] and recently updated to MitoMiner v4.0 [20] . High-throughput screening (HTS) and next generation sequence (NGS) has emerged as powerful tools to completely characterize the mitochondrial proteome. Our group has previous experience in identifying novel mitochondrial genes. We demonstrated that the coiled coil domain-containing protein 56 (CCDC56) is a mitochondrial protein essential for cytochrome c oxidase function in Drosophila melanogaster [21] and its human ortholog, COA3, stabilizes cytochrome c oxidase I and promotes cytochrome c oxidase assembly [22] . In addition, we observed that GATC was a new Drosophila melanogaster protein, ortholog to the corresponding subunit of the bacterial Glutamyl-tRNAGln amidotransferase, and candidate for mitochondrial localization. We described that this amidotransferase activity is essential for mammalian mitochondrial translation in vivo [23] and recently that mutations in any of its subunits (GATA, GATB and GATC) provoke severe mitochondrial diseases [24] . Ccdc56 and GatC are transcribed in bicistronic mRNAs in Drosophila melanogaster together with the mitochondrial translation factor mt-Tfb1 gene and the mitochondrial DNA polymerase PolγB subunit respectively [21] (Peña et al. manuscript in preparation).
The C4884 Drosophila gene is also transcribed in a bicistronic mRNA together with the uncharacterized gene CG42487. The C4884 ortholog gene in humans is the C6orf203 gene. The nDNA-encoded C6orf203 gene is located in the long arm of the chromosome 6 (6q21), and it is predicted to possesses a conserved domain that belongs to the RNAbinding S4 domain superfamily (IPR036986). Interestingly, C6orf203 has been included into the MitoCarta+ and MitoMiner v4.0 databases as a mitochondrial uncharacterized protein, showing, in addition, a high score for mitochondrial location using the algorithm for prediction of mitochondrial targeting sequences MITOPROT (https://ihg.gsf.de/ihg/mitoprot.html; [25] ). Moreover, previous evidences strongly suggest mitochondrial location of C6orf203. In 2011, C6orf203 was identified as a mitochondrial phosphoprotein with unknown function in human muscle [26] and it was present, together with a number of mitochondrial ribosome proteins, when the mitoribosomal subunit ICT1 was immunoprecipitated [27] . A few weeks ago, it was described that C6orf203/MTRES1 is a mitochondrial protein involved, acting at the transcriptional level, in maintaining mitochondrial RNA levels under stress mediated by mtDNA depletion provoked by BrEt treatment [28] .
In this work, we describe that C6orf203 is part of the mitochondrial proteome that is evolutionarily conserved from insects and worms to mammals. We demonstrate by CRISPR/Cas9 genomic editing its participation in OXPHOS biogenesis under normal culture conditions. Moreover, we demonstrate the presence of C6orf203 in very high molecular weight complexes and its involvement in mitochondrial protein biosynthesis.
We propose C6orf203 as a strong candidate to be considered in the search of genes responsible for mitochondrial pathology not necessarily severe.
RESULTS

C6orf203 is evolutionary conserved and contains an RNA binding domain
Previously, our laboratory showed that orthologs of some highly conserved and essential genes for the OXPHOS system biogenesis in humans such as mt-Tfb1, GatC, Pol-β and Coa3 were encoded on bicistronic mRNAs in Drosophila [21] (Peña et al. manuscript in preparation). Since this arrangement, unusual in eukaryotes, could suggest a tendency for mitochondrial genes in this organism we delved into the search and identified the CG4884 gene also encoded on a bicistronic mRNA. The human ortholog of CG4884 is C6orf203, recently described as a mitochondrial RNA binding protein.
Although three C6orf203 mRNA isoforms are shown (ENSG00000130349), they code only for two putative inmature proteins of 240 and 245 amino acids in length respectively. However, both of them render a unique mature functional protein of 156 amino acids according to the predicted mitochondria targeting sequence which extends amino acids 1-84 ( Fig 1) . C6orf203 is a protein well conserved in Metazoa, from Drosophila to humans, being absent in bacteria, fungi and plants. Based on Interpro [41] and NCBI CDD [42] domain annotation tools and previous work [28] C6orf203 harbors an RNA binding domain ( Fig 1) essential for ribosome function in bacteria [43] and for mitochondrial transcription in humans [28] .
C6orf203 is a mitochondrial matrix protein that interacts with the Mitochondrial Inner Membrane
To confirm the mitochondrial localization of human C6orf203, we transiently expressed the C-terminal GFP-tagged construct in both HEK293T and HeLa cells. As shown in (Fig 2A) , C6orf203-GFP colocalized with the mitochondrial marker Mitotracker Red in both cell types.
To determine the sub-mitochondrial location of the endogenous C6orf203, mitochondria from HEK293T cells were isolated and incubated with proteinase K (PK) together with an iso-osmotic buffer or a hypo-osmotic buffer in order to induce mitochondrial swelling. The mitochondrial swelling causes the outer membrane rupture. Our results confirm that C6orf203 is protected from degradation by PK when mitochondria were swollen ( Fig 2B) , similar to MnSOD, a well-characterized mitochondrial matrix protein, strongly suggesting that C6orf203 is located within the mitochondrial matrix. In order to determine a putative association of C6orf203 to the IMM, we perform a carbonate extraction assay ( Fig 2C) . We used well-known selected markers such as MT-CO1 (an integral IMM protein), SDHA (a peripheral IMM protein) and MnSOD (a soluble matrix protein). The behavior of C6orf203 was similar to that of SDHA, strongly suggesting that C6orf203 is a mitochondrial matrix protein with a weak association to the internal face of the IMM as has been observed for other proteins involved in different processes such as COQ8B (coenzyme Q biosynthesis) [44] or some mitochondrial translational activators such as Mba1 [45] or PET111 [46] .
In this analysis, we also observed that the molecular weight of the mature form of C6orf203 is 19 kDa, which corresponds well with the predicted N-terminal cleavage of 84 aminoacids (Mitoprot).
Generation of C6orf203-KO cell lines
To obtain a human cell model to study the function of C6orf203, we generated HEK293T Knockout cells (C6orf203-KO) using the genomic edition system CRISPR/Cas9n(D10A) nickase as described in Materials and Methods. This enzyme was targeted by two gRNAs with specific recognition sites on different genomic DNA strands of C6orf203 exon 3 ( Fig 3A) . gRNAs recognition sites were separated by 76 bp, producing nicks that are recognized by the cell as a single injury creating insertions and deletions during repair [30] . The region between gRNAs encompassed the first coding exon, which includes the beginning of its RNA binding domain ( Fig 3A) .
24 hours after transfection of HEK293T cells with plasmid expressing gRNAs and CRISPR/Cas9n(D10A) nickase, we analyzed by PCR the edited region in pooled cells as described in Materials and Methods and Fig EV 1 legend. The efficiency of edition was approximately 65%, prompting us to generate clones from the pool ( Fig EV 1 ).
Analysis of 36 individual clones by western blot revealed that 6 of them had no detectable levels of C6orf203 ( Fig 3B) . The genomic analysis of these C6orf203-KO clones was carried out by PCR of the edited region, cloning on an E.coli vector and sequence 21 clones, showing deletions in C6orf203 alleles provoking frameshifts, and therefore premature stop codons and truncated versions of C6orf203, and deletions in the final version of C6orf203 (Table EV 1 ).
The absence of C6orf203 leads to a decrease in mitochondrial function
As a first approach to determine whether C6orf203 disruption could affect mitochondrial function, we first analyzed the capability of the C6orf203-KO clones to growth in a medium containing galactose as a carbon source. Galactose entry on glycolysis involve several limiting enzymatic steps (Leloire pathway) [47] so that a functional OXPHOS system can maintain energetic metabolism in those conditions but a non-functional OXPHOS system cannot, severely affecting cell growing or even provoking cell death. C6orf203-KO cells grew slightly slower than HEK293T wild type cells in high glucose medium but were unable to grow in galactose containing medium ( Fig 4A) , indicating that C6orf203 is required for a proper mitochondrial OXPHOS function.
In order to confirm a mitochondrial dysfunction, we next measure the oxygen consumption in intact cells. The results revealed a reduction of approximately 35% in basal oxygen consumption in the six selected C6orf203-KO clones when compared to control cells ( Fig   4b) , confirming the respiratory chain defect of cells lacking C6orf203.
For further studies, C6orf203-KO clones 5 (from hereon C5) and 35 (from hereon C35) were used. Thus, in order to demonstrate that the functional defects observed in C6orf203-KO cells were due to the absence of C6orf203, we carried out rescue studies via ectopic stable expression of the Flag-tagged version of C6orf203 in C5 and in C35 clones, rendering C5-Flag and C35-Flag cell lines ( Fig 5A) . C6orf203-Flag expression was able to fully rescue the growth rate defect in galactose ( Fig 5B) as well as the respiration defect (Fig 5c) in both KO cell lines. This confirmed that the phenotypes observed in knockout cells was due to C6orf203 edition, discarding an off-target effect and confirming that C6orf203-Flag was a functional version of C6orf203.
Finally, we analyzed the mitochondrial ATP synthesis under glycolysis inhibition conditions by action of 2-deoxy-D-glucose/1 mM pyruvate. Results revealed a decrease between 60%-40% in mitochondrial ATP production in C5 and C35 cell lines respectively, which reach normal values when expressed C6orf203-Flag in C5-Flag and C35-Flag cells.
In addition to the in vivo analysis of the carbon source dependent growing rate, the oxygen consumption capability and the mitochondrial ATP synthesis of C6orf203-KO cells compared to control cells we further investigated several other parameters of the molecular phenotype induced by lacking C6orf203 using in vitro approaches.
Lacking C6orf203 leads to a reduction in the respiratory chain complexes activities
To further investigate the function of C6orf203 we analyzed if the respiratory defect observed in C6orf203-KO cells was the result of a defect in the respiratory chain complexes activity. Thus, we observed a reduction of 60% in complex I activity and a reduction of 50% in complex III and IV compared to control cells ( Fig 6A) . Activity of complex II, which is exclusively formed by nuclear encoded subunits, as well as citrate synthase, remained unchanged ( Fig 6A and 6B respectively) , strongly suggesting an OXPHOS alteration of mitochondrial origin. The defect in the respiratory chain complexes activity was restored by expression of C6orf203-Flag.
C6orf203 depletion induces defects in the formation of fully-assembled OXPHOS complexes and reduces the steady-state levels of respiratory chain components
In order to gain insight regarding the reduction of respiratory chain complexes activities, we next analyzed the steady state levels of fully-assembled OXPHOS complexes. Thus, mitochondrial extracts were obtained under native conditions and resolved using bluenative PAGE (BN-PAGE). Analysis by Western Blot using antibodies against subunits of specific complexes showed a decreased in complex I ( ̴ 60%), complex III ( ̴ 50%), complex IV( ̴ 50%) and complex V ( ̴ 50%) in C6orf203-KO cells compared to control cells ( Fig   7a) , consistent with the reduction of complexes activities seen before. Relative values of signals were measured by densitometry for each line and complex ( Fig 7B) . Our results also showed a reduction in fully assembled complex V and revealed accumulation of ATPase subcomplexes ( Fig 7C) , that were confirmed by 2D BN/SDS-PAGE ( Fig 7D) . These data strongly suggest that the reduction in OXPHOS complex activities is due to a decrease in the steady state levels of fully-assembled OXPHOS complexes.
We next determined whether changes in OXPHOS structural subunit steady-state levels were responsible for the alteration of assembled complexes. For that purpose, we performed western blot analysis using antibodies for a representative number of OXPHOS subunits ( Fig 7E) . We observed a clear reduction of the mitochondrial-encoded complex IV subunits MT-CO1 and MT-CO2 as well as MT-ND1, a complex I subunit, in C6orf203-KO cells compared to wild type cells. We also observed a reduction in NDUFB8 and UQCRC2 levels, two nuclear-encoded complex I and complex III subunits, respectively, which are unstable if are not incorporated into their corresponding complexes [24] . Taken together, these observations explained the sum of our previous results, and demonstrate that the absence of C6orf203 leads to a reduction of the steady state levels of mtDNA encoded OXPHOS subunits.
C6orf203 knockout leads to a reduction in the mitochondrial protein synthesis de novo
A global reduction of the levels of OXPHOS subunits may be fundamentally due to mtDNA depletion, defects in mtRNA synthesis and/or processing or dysfunctional mitochondrial protein synthesis. Thus, we first analyzed the mtDNA content of Hek293T and C6orf203-KO cells C5 and C35 by qPCR. No significant changes were observed ( Fig EV 2) , demonstrating that the OXPHOS defects associated to the lack of C6orf203 expression were not a consequence of mtDNA depletion.
Then, we analyzed the levels of mitochondrial RNAs of the same cell lines by RT-qPCR using specific probes for 12S-rRNA, MT-CO1, MT-CO2, MT-ND1 and MT-ND6 genes. As it is shown in (Fig EV 2B ), no significant changes were obtained, strongly suggesting that the absence of C6orf203 had no effect on the steady-state levels of mtRNAs. In order to confirm this point and to analyze the processing of mtRNAs, we carried out northern experiments. Thus, after resolving total mtRNA from Hek293T, C5 and C35 cell lines on agarose-formaldehyde gels, we transferred them to nitrocellulose and hybridized with specific ssRNA antisense probes corresponding to 16S-rRNA gene (or MT-RNR2), MT-CO1 and MT-ATP8 genes. No changes were observed either in the amount or in mtRNAs intermediates ( Fig EV 2C) , strongly suggesting that there is no alteration of mtRNA processing in C6orf203 knockout cells and confirming the previous evidence that the steady-state levels of mtRNAs do not change.
Finally, we performed pulse-labeling experiments to analyze the de novo mitochondrial protein synthesis. Thus, WT, C5, C35, C5-Flag and C35-Flag cell lines were treated with emetine to inhibit cytoplasmic translation and then 35 S-Methionine was added to the medium for 90 minutes to incorporate specifically into the mitochondrial translation products. We found that absence of C6orf203 significantly reduces the mitochondrial capacity to translate their mt-mRNAs ( Fig 8A) . Densitometry of translation products and analysis estimated this reduction in approximately 35%-40% ( Fig 8B) .
These data demonstrate that C6orf203 is involved in the OXPHOS system biogenesis through its participation in a very important but not essential manner in mitochondrial protein biosynthesis. Table 2 ). In addition, analysis using the NCBI Resources Genes showed 37 putative interactors with C6orf203, 16 of which were
C6orf203 forms high molecular weight complexes
MRPLs and 1 was a MRPS (Supp Table 2 ). Finally, STRING Interaction Network [50] showed 58 proteins that putatively could interact with C6orf203, 15 of them were members of the mitoribosome. Within the top 25 interactions 7 were mitoribosome proteins (Table EV 2 ).
Then, in order to confirm the possibility that C6orf203 may interact or form part of high molecular weight protein complexes, perhaps the mitochondrial ribosome, we used the cell line HEK293T expressing a TAP-tagged version of C6orf203. Their mitochondria were isolated, solubilized with the relative soft detergent digitonin and subjected to 2D BN/SDS-PAGE followed by Western blot analysis. Our results revealed that C6orf203-TAP was part of several complexes ranging in size from monomeric C6orf203-TAP to high molecular weight complexes. By comparison with the observed supercomplex I+III 2 +IV (SC) signal, as revealed by anti-NDUFS2 antibody, C6orf203 forms part of a supercomplex of approximately 1,500 kDa in size ( Fig 9A) . These results were confirmed by isokinetic sucrose gradients. This analysis confirmed that C6orf203 forms complexes from low (probably the monomer) to very high molecular weight, being particularly enriched in the fractions corresponding to the 39S mitochondrial ribosome large subunit (mtLSU) ( Fig 9B) .
Mitoribosome assembly is not affected by the lack of C6orf203
Our results pointed towards the involvement of C6orf203 in mitochondrial translation being part of high molecular weight complexes that well could correspond to mitochondrial ribosomes. In order to test if C6orf203 was involved in mitoribosomes formation, we analyzed the mitochondrial ribosome biogenesis profile on sucrose gradients followed by Western blot using antibodies recognizing the markers MRPS22, a member of mt-SSU or 28S small subunit, and MRLP49, a subunit of mt-LSU. Thus, we analyzed mitochondria from wild type, C5 and C35 cell lines.
Distribution of MRLP49 and MRPS22 was similar in all cell lines used, strongly suggesting that absence of C6orf203 did not lead to a mitoribosome biogenesis defect ( Fig 10) . However, it cannot be ruled out it is involved in mitoribosomes function.
Discussion
Mitochondrial OXPHOS function is the result of a coordinated collaboration of hundreds of proteins, of which many are still to be identified and characterized. As such, the identification and characterization of all OXPHOS players is essential to fully understand the complex physiology of this essential biological process. Furthermore, by fully understanding the physiology of the mitochondria we can better comprehend mitochondrial dysfunctions, which result in mitochondrial OXPHOS diseases. Thus, discovering missing OXPHOS-related functional genes opens up the possibility of understanding, diagnosing and of thinking about possible therapeutic approaches for patients with OXPHOS diseases. In our lab, by data mining the Drosophila genome and by ortholog analysis, we have identified several genes essential for mitochondrial function, which are coded within bicistronic mRNAs [23] [22, 24] , leading us to suggest that this arrangement of mitochondrial genes may be a tendency in this organism (manuscript in preparation). A few weeks ago, Kotrys and collaborators, by a proteomic analysis of the human mitochondria, identified C6orf203/MTRES1 as a new mitochondrial gene [28] . They describe this protein as a factor that, acting at transcriptional level, prevents mitochondrial transcription deficiency under mtDNA depletion induced by BrEt. In our study, we describe the identification of C6orf203/MTRES1 by a different approach, and via its characterization we describe a radical and novel function for C6orf203/MTRES1 in OXPHOS system biogenesis, different than that described by Kotrys et al.
Our analysis of bicistronic mRNAs in Drosophila also identified C6orf203. In addition,
C6orf203 showed a putative efficient mitochondrial targeting sequence (MTS), a conserved RNA binding domain, it was included in MitoCarta, was coimmunoprecipitated with ICT1, an integral component of the human mitoribosome [27] and it was evolutionary conserved. All these evidences made C6orf203 a very interesting gene and worthy of study.
Using the CRISPR/Cas9 genomic edition system in HEK293T cells, an actively respiring cell line, we obtained 6 clones with different edited versions where C6orf203 was not expressed in 5 of them or it was expressed a truncated non-functional version, making these clones the best and easiest model to study and understand the function of Moreover, the processing of the selected mtRNAs analyzed were also not affected. In contrast, however, in C6orf203-KO cell lines the capacity to synthesize mitochondrial proteins was significantly affected, suggesting that C6orf203 is instead a mitochondrial translation factor, as its physical interaction with the mitochondrial ribosome subunit ICT1 suggested. These results revealed an unexpected new role for C6orf203, being its involvement in translation under normal growing conditions in addition to working as a mitochondrial transcript protection factor. This also reinforced the relevance of using appropriate systems, such as the C6orf203-KO cells described, in order to understand the real biological involvement of putative OXPHOS proteins.
Our subcellular fractionation study revealed that C6orf203 behaved as a soluble protein located on the mitochondrial matrix and interacting with IMM. This observation, together with its involvement in mitochondrial translation, its physical interaction with the mitoribosome subunit ICT1 and the well-known interaction of mitoribosome with IMM [51, 52], made us analyze the distribution of C6orf203 in a sediment coefficientseparating sucrose gradient, in comparison with mitoribosome subunits. We confirmed that C6orf203 formed part of very high molecular weight complexes, also confirmed by 2D BN/SDS-PAGE, perhaps the mitoribosome itself. Along these lines, several on-line resources specialized in the analysis of protein-protein interactions, strongly suggested the interaction of C6orf203 with the mitoribosome, showing percentages between 23.8% and 45.9% of mitoribosome proteins as C6orf203 interactors. Since the factors that participate into mitoribosome biogenesis remain largely unknown, we analyzed the putative involvement of C6orf203. The similar kinetics of mitoribosome subunits assembly in wild type cells and in C6orf203-KO cells discarded this possibility;
however, although the decrease in mitochondrial translation rate in C6orf203 knockout cells is not due to a defect in mitoribosome assembly, it cannot be ruled out that
C6orf203 depletion leads to a serious but not deleterious defect in mitoribosome function. Thus, the specific role of C6orf203 in the synthesis of mitochondrial proteins is still unknown and requires future work. We hypothesize that it could be a member of the mitoribosome with an important but not essential function in the translation process, or it could be a translation activator similar to others IMM-interacting proteins such as Mba1 [45] or PET111 [46] . Furthermore, the phosphorylation of C6orf203 at Ser-106/Ser-110 by a still unknown Kinase [26] suggests that this protein could participate in regulatory events depending on the cellular context.
A final and significant consequence of this work is the possible clinical expression of an important but not complete defect in translation by lack of C6orf203 function.
Therefore, patients with a suspected mitochondrial disease caused by C6orf203 mutations probably will not show a deleterious but rather a mild phenotype, unless a synergistic effect with other mutated genes exists. In addition, the apparent double function of C6orf203 as a protector of transcription under mtDNA depletion or as a regulator of translation under normal conditions will surely have different clinical manifestation depending on the degree to which each function is affected. Thus, our study complements, in a timely manner, the conclusions recently derived by Kotrys and collaborators [28] .
In conclusion, this work confirms that C6orf203 is a soluble protein located on the mitochondrial matrix, interacting with IMM, which form part of high molecular weight complexes, co-sediments with mitoribosome subunits and is involved in regulating mitochondrial protein synthesis under basal conditions. C6orf203 is therefore a good candidate to be included in clinical panels of genes to identify the origin of some, likely mild, mitochondrial pathologies. Briefly, one day before transfection penicillin/streptomycin were removed from the culture medium. When reached 60-80% confluence, cells were co-transfected with the C6orf203-TAP construct and with plasmid pOG44 using Superfect (Qiagen). After 48h, cells were selected by the addition of blastidicin and hygromycin (Invitrogen). Clones were selected and, when reaching 60-80% confluency, protein expression was induced by using 1 μg/ml doxcycline (Sigma Aldrich) for 24h.
Materials and methods
Constructs
Some constructs were obtained from HEK293T cDNA. Thus, total RNA was previously extracted from cells using the TRIzol® reagent (Sigma) following the manufacturer's instructions. For cDNA synthesis, the High-Capacity cDNA Reverse Transcription kit (Life Technologies) with 1 μg of total RNA was used.
To construct the C-terminal Flag-tagged version of C6orf203, its cDNA was amplified without the stop codon using the forward primer 5´-CATCTTAAGATGGCTATGGCTAGTGTTAA-3´ and the reverse primer 5´-TAGCGGCCGCTTACTTGTCGTCATCGTCTTTGTAGTCTTTAGACATTCTCTTC T-3´ that contains the Flag tag (underlined) in frame with C6orf203 coding region and the restriction sites for AflII and NotI (bold and italic), respectively. The PCR product was cloned into the vector pIRESpuro2 using those restriction enzymes (Clontech).
To express C6orf203 fused to eGFP (Enhanced Green fluorescent protein), the C6orf203 coding sequence lacking the stop codon was amplified by PCR using the forward primer 5´-CCACTCGAGATGGCTATGGCTAGTGTTAAA-3´ and the reverse primer 5´-CCAGGATCCTTAGACATTCTCTTCTTAGG-3´ that contain the restriction sites for XhoI and BamHI (bold and italic), respectively. The PCR product was cloned into the corresponding restriction sites of pEGFP-N1 vector (Clontech).
A doxycyclin inducible C6orf203-TAP-tagged (C6orf203-TAP) expression vector was constructed as described in [29] . Final construct was transfected into Flp-In T-Rex HEK293 cells as described above.
Cloning for expression of gRNAs and Cas9 for genome editing is described below.
Accuracy of all clones was confirmed by DNA sequencing. 
Generation of C6orf203 deficient cell lines using CRISPR/Cas9 nickase system
Subcellular localization of C6orf203
To analyze the subcellular localization of C6orf203, HEK293T or Hela cells were transiently transfected with the peGFP-N1 derivative construct that expresses C6orf203 fused to eGFP at its C-terminal. 24 hours after transfection cells were incubated with medium containing 100 nM MitoTracker Red CMXRos (Thermo Scientific), a mitochondrion-selective dye, for 30 min at 37°C. Cells were washed twice with PBS and fixed with 4% PFA for 20 min. After three washes with PBS, images were obtained in a confocal microscope with a 63x oil objective (Carl Zeiss LSM 700, Oberkochen,
Germany).
Mitochondrial subfractionation, proteinase K protection assay and carbonate extraction
An enriched mitochondria fraction was previously isolated from 4x10 7 HEK293T cells by differential centrifugations following the protocol described in [32] . Then, the mitochondrial fraction was purified by ultracentrifugation at 100,000 g for 2 hours in a discontinuous sucrose gradient (five fractions from 1.6 M to 0,8 M sucrose). Purified mitochondria were obtained from the sucrose 1.4/1.2 M interphase and washed.
Proteinase K protection assay was performed as described in [33] Both samples were resolved on a 12% SDS-PAGE gel and analyzed by immunoblotting.
Growth curves
Cell growth was determined by seeding 2.5x10 4 cells/well of wild-type HEK293T, 
Measurement of oxygen consumption
Wild-type HEK293T cells, C6orf203-KO cells and C6orf203-KO cells expressing the flag-tagged version of C6orf203 were grown in DMEM medium containing 0.9 g/l galactose for 12 hours. Intact cells were then collected and their basal respiration was measured in DMEM-galactose using a Clark-type oxygen electrode (Hansatech Instruments) as described [34] . Assays were performed in three independent experiments.
ATP measurement
Measurement of mitochondrial steady-state ATP levels was carried out in cells incubated with 5 mM 2-deoxy-D-glucose/1 mM pyruvate and no carbon source using the luminometric luciferin-luciferase-based method (CLS II, Roche Applied Science) as described in [35] . Experiments were performed in duplicate on at least three independent days.
Enzymatic activity of OXPHOS complexes
The activity of the respiratory chain complexes and the enzyme citrate synthase was measured as previously described [36] using a Beckman Coulter DU 800 spectrophotometer.
Pulse labeling of mitochondrial translation products
Synthesis of mtDNA encoded proteins was analyzed by pulse labeling experiments according to [37] with some modifications. Briefly, exponentially growing 4x10 
DNA isolation and quantification of mtDNA
Total DNA was isolated from cultured cells using a commercial kit (Qiagen, UK), following the manufacturer's recommendations. The mtDNA content in 50 ng of total DNA was measured by SYBR green real-time polymerase chain reaction (PCR) using the Applied Biosystems Step-One Plus real-time thermocycler according to [24] consisting of an initial 10 min denaturation step at 95°C followed by 40 cycles of denaturation (15 sec at 95°C) and annealing/extension (1min at 60°C). The analyzed genes were the mitochondrial 12S-rRNA gene (or MT-RNR1) and the nuclear HPRT1 mtDNA copy number values were expressed by the ratio 12S rRNA/HPRT1.
mtRNA content and intermediates
Total RNA was extracted and cDNA synthesized as in "Constructs" section followed by qPCR using conditions as detailed in the previous point. In order to analyze mtRNAs intermediates, and like an additional approach for mtRNA quantification, northern blot assays were carried out according to [38] . Briefly, 5 μg of total RNA from wild-type HEK293T and C6orf203-KO cells were resolved on a 1.5% agarose gel containing 18% formaldehyde and transferred to a ZETA-PROBE GT membrane (Bio-Rad). Probes used for hybridization were 32 rRNA gene, MT-CO1 and MT-ATP8/6 riboprobes were 399 nts., 343 nts. and 450 nts in size respectively. Gels were transferred to a Zeta-Probe membrane (Bio-Rad) that was subjected to a 1200x100 μJ/cm 2 . Later, the membranes were incubated with PerfectHyb Plus Hybridization Buffer (Sigma) for 2 hours at 60ºC before addition of denatured riboprobes. The riboprobes were incubated at 60ºC overnight and the membranes were washed and developed using x-ray films.
Immunoblotting (Western Blot)
Cellular or mitochondrial pellets were resuspended in RIPA lysis buffer and protein extracts obtained as above. Equal amounts of protein (50 to 100 µg) were subjected to denaturing SDS-PAGE (regularly 12% polyacrylamide gels) resolution and then 
Blue Native-PAGE and Two-dimensional BN/SDS-PAGE
Blue Native PAGE (BN-PAGE) and two-dimensional BN/SDS-PAGE experiments were performed as previously described [39] .
Sucrose gradient analysis of mitoribosomes
Mitoribosomes were purified on sucrose gradients as previously described [40] . were designed to recognize the first nucleotides coding the conserved RNA binding domain showed in Fig 1. The PAM sequence is shown highlighted in orange.
B Immunoblot analysis of mitochondrial extracts from wild type HEK293T cells (WT)
and C6orf203-KO clones (C1, C2, C5, C9, C11, C35) using anti-C6orf203 antibody.
VDAC was used as loading control. 25 g of purified mitochondrial protein were resolved in a 12% by SDS-PAGE. All but clone 9 showed no expression of C6orf203.
Clone 9 expressed a truncated form of the protein. presented as means ± standard deviation. There were no significant differences. n=4. C Northern blot assays were carried out using 5 μg of total RNA from wild type, C5
and C35 cells run in agarose gel containing 18% formaldehyde (lower panels; loading controls) and transferred to ZETA-PROBE GT membrane (Bio-Rad). Probes used for hybridization were 32 P-labeled specific antisense ssRNAs corresponding to 16S-rRNA gene (or MT-RNR2), MT-CO1 and MT-ATP8/6 genes. The riboprobes were incubated at 60ºC overnight and the membranes were washed and developed using x-ray films (upper panels). No significant differences were seen in the mtRNAs forms. Since the gels are from different experiments the scale is not the same and it is not possible to superimpose the images. The interactors assigned to c6orf203 by three different resources are shown in an Excel file. The Harmonizome collection, managing proteins from 114 datasets, shows 260 proteins (in three columns) candidate to interact with C6orf203 from which 23,8% are members of mitoribosome (squared). The NCBI resources assign to 37 proteins the possibility to interact with C6orf203, belonging 45,9% to the mitochondrial ribosome (squared). In its turn, STRING Interaction Network shows 58 proteins with different evidences of interaction with C6orf203. From the later, 25,8% are mitochondrial ribosome proteins (squared). AARS2  MALSU1  NDUFS2  APP  ACSF2  AASS  MCAT  NDUFS3  ARL2  AFG3L2  ABCB7  MCCC2  NDUFS8  ATP5F1E  ALDH3A2  ACAD9  MCU  NDUFV1  ATP5PO  APP  ACADVL  MDP1  NGRN  C1QBP  ATP5F1C  ACOT11  ME2  NIPSNAP1  CDK1  ATP5F1E  ACOT9  METTL17  NME4  COPS5  ATP5PO  ADCK3  MIEN1  NOA1  CPNE7  C1QBP  AFG3L2  MMAB  NRD1  ECH1  CHCHD2  AGK  MOV10  NRF1  INTS3  CLPB  AIFM1  MRM1  NSUN4  MED17  COPS5  ALDH18A1  MRPL1  NT5C  MED23  COQ9  ALDH1B1  MRPL10  OAT  MRPL1  CPNE7  ALDH1L2  MRPL11  OXA1L  MRPL13  CPS1  ALDH2  MRPL12  OXR1  MRPL14  CPT2  AP2M1  MRPL13  PARP4  MRPL16  DNAJC19  APOE  MRPL14  PARS2  MRPL19  ECH1  APP  MRPL15  PCCB  MRPL2  ERAL1  ATAD3A  MRPL16  PDK3  MRPL21  INPP5E  ATAD3B  MRPL17  PGAM5  MRPL22  MAIP1  ATP5A1  MRPL18  PHB  MRPL32  MCCC1  ATP5B  MRPL19  PHB2  MRPL33  MRPL1  ATP5C1  MRPL2  PMPCA  MRPL35  MRPL13  ATP5F1  MRPL20  PMPCB  MRPL40  MRPL14  ATP5H  MRPL21  PNPT1  MRPL46  MRPL16  ATP5L  MRPL22  POLDIP2  MRPL53  MRPL2  ATP5S  MRPL23  POLRMT  MRPL58  MRPL21  BDH2  MRPL24  PRDX4  MRPL9  MRPL22  BOLA2  MRPL27  PRDX5  MRPS14  MRPL32  BTF3L4  MRPL28  PRMT1  NDUFV1  MRPL33  C10ORF2  MRPL3  PTCD1  NOL8  MRPL35  C11ORF73  MRPL32  PTCD3  NRDC  MRPL40  C1QBP  MRPL37  PUS1  PMPCA  MRPL46  C9ORF142  MRPL39  PUSL1  POLDIP2  MRPL53  CECR5  MRPL4  PYCR2  RCC1L  MRPL58  CHCHD1  MRPL40  RABGGTB  SLC30A9  MRPL9  CLPX  MRPL41  RARS2  STRAP  NDUFA5  CLU  MRPL43  RBFA  NDUFAF4  COPS5  MRPL44  RNMTL1  NDUFS2  COX4I1  MRPL46  RPS15  NDUFS3  CPT2  MRPL47  RPUSD3  NDUFV1  DAP3  MRPL48  RPUSD4  NRDC  DBT  MRPL49  SARS2  OCIAD1  DDX28  MRPL50  SDHA  PMPCA  DHX30  MRPL51  SFXN1  PMPCB  DIAPH1  MRPL54  SHMT2  POLDIP2  DLD  MRPL55  SLC25A1  RCC1L  DNAJA3  MRPL9  SLC25A10  SDHAF4  ECH1  MRPS10  SLC25A11  SFXN4  ECI1  MRPS11  SLC25A12  SLC25A19  EEF1B2  MRPS14  SLC25A13  SLC25A5  EIF4A3  MRPS15  SLC25A18  SLC30A9  EIF5B  MRPS16  SLC25A3  SPG7  ERAL1  MRPS17  SLC25A4  STRAP  ERLIN2  MRPS18A  SLC25A5  TARS2  ETFA  MRPS18B  SLC25A6  TIMM21  FARS2  MRPS2  SLIRP  TIMM44  FASTKD1  MRPS21  SNCA  XPNPEP3  FASTKD2  MRPS22  SSBP1  FLAD1  MRPS23  STOML2  GADD45GIP1  MRPS24  STRAP  GFER  MRPS25  SUCLA2  GLDC  MRPS26  SUGT1  GLUD1  MRPS27  SULT1A2  GRPEL1  MRPS28  SUPV3L1  GRSF1  MRPS30  TARS2  GTPBP10  MRPS31  TEFM  H1F0  MRPS34  TFAM  HADHA  MRPS35  TFB1M  HARS2  MRPS5  THNSL1  HK1  MRPS6  TIMM21  HNRNPDL  MRPS7  TMLHE  HSD17B10  MRPS9  TOP1  HSPA1B  MRRF  TRMT10C  HSPA9  MTG1  TRUB2  HSPD1  MTIF2  TUFM  ICT1  MTIF3  UBC  IGF2BP2  MTPAP  UFM1  IMMT  MUT  UQCRC1  ISCA1  MYO18A  UQCRC2  KARS  NDUFA13  UQCRFS1  KIAA0391  NDUFA9  VARS2  KIF1BP  NDUFAF3  VDAC1  LETM1  NDUFB4  VDAC3  LONP1  NDUFB8  WBSCR16  LRPPRC  NDUFS1  YARS2  YME1L1  ZBTB8OS   Harmonizome 
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